MECTACER BIOLOX FORTE-FEMORAL HEADS

K073337 · Medacta International S.A. · LZO · Feb 13, 2008 · Orthopedic

Device Facts

Record IDK073337
Device NameMECTACER BIOLOX FORTE-FEMORAL HEADS
ApplicantMedacta International S.A.
Product CodeLZO · Orthopedic
Decision DateFeb 13, 2008
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 888.3353
Device ClassClass 2
AttributesTherapeutic

Intended Use

The MectaCer BIOLOX® forte Femoral Heads are intended for mechanical fixation to a mating hip stem and indicated for treatment of patients who are candidates for total or partial hip arthroplasty in primary or revision surgery. The patient should be skeletally mature. The patient's condition should be due to one or more of the following: Severely painful and/or disabled joint as a result of osteoarthritis, post-traumatic arthritis, rheumatoid arthritis, or psoriatic arthritis. Congenital hip dysplasia. Ankylosing spondylitis. Avascular necrosis of the femoral head. Acute traumatic fracture of the femoral head or neck. Failure of previous hip surgery: joint reconstruction, internal fixation, arthrodesis, hemiarthroplasty, surface replacement arthroplasty or total hip replacement where sufficient bone stock is present.

Device Story

MectaCer BIOLOX® forte Femoral Heads are ceramic ball components for hip arthroplasty; designed for mechanical fixation to mating hip stems. Device replaces damaged hip joints to reduce pain and increase mobility. Used in primary or revision surgery by orthopedic surgeons in clinical/hospital settings. Fabricated from high-purity alumina ceramic; available in 28, 32, and 36 mm diameters. Device provides structural interface between femoral stem and acetabular component.

Clinical Evidence

Bench testing only. No clinical data provided. Testing included static load resistance (ISO 7206-10) and axial disassembly force (ASTM F-2009-00) to verify mechanical performance against established standards for ceramic hip components.

Technological Characteristics

Material: High-purity aluminium oxide ceramic (Al2O3) per ISO 6474:1994. Form factor: Modular femoral ball heads (28, 32, 36 mm diameters). Connection: Taper interface for mechanical fixation to hip stems. Sterilization: Radiation per AAMI/ANSI/ISO 11137.

Indications for Use

Indicated for skeletally mature patients undergoing total or partial hip arthroplasty (primary or revision) due to osteoarthritis, post-traumatic/rheumatoid/psoriatic arthritis, congenital hip dysplasia, ankylosing spondylitis, avascular necrosis, acute traumatic fracture, or failed previous hip surgery.

Regulatory Classification

Identification

A hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis is a device intended to be implanted to replace a hip joint. This device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. The two-part femoral component consists of a femoral stem made of alloys to be fixed in the intramedullary canal of the femur by impaction with or without use of bone cement. The proximal end of the femoral stem is tapered with a surface that ensures positive locking with the spherical ceramic (aluminium oxide, A12 03 ) head of the femoral component. The acetabular component is made of ultra-high molecular weight polyethylene or ultra-high molecular weight polyethylene reinforced with nonporous metal alloys, and used with or without bone cement.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ K073337 (fg 1 of 3) Image /page/0/Picture/1 description: The image shows the logo for Medacta International. The logo consists of a stylized black graphic to the left of the word "Medacta" in black lowercase letters. Below "Medacta" is the word "International" in a smaller font, also in black. To the right of "International" is a small graphic of a plus sign. #### 510(k) Summary FEB 13 2008 Manufacturer: MEDACTA International SA Strada Regina CH6874 Castel San Pietro Switzerland Phone (+41) 91 696 60 60 (+41) 91 696 60 66 FAX - Contact Person: Ms. Natalie J. Kennel Consultant NJK & Associates, Inc. 13721 Via Tres Vista San Diego, CA 92129 USA Phone: (858) 705-0350 Fax: (858) 764-9739 email: NKennel@nikconsulting.com Date Prepared: February 4, 2008 #### DEVICE INFORMATION Trade/Proprietary Name: MectaCer BIOLOX® forte Femoral Heads Common/Classification Name: Hip Joint, metal/ceramic/polymer, semiconstrained, cemented or non-porous uncemented prosthesis 21 CFR 888.3353 Class II Device Product Code: LZO Predicate Devices: The MectaCer BIOLOX® forte Femoral Heads are substantially equivalent to Plus Ceramic Ball Heads 28, 32 & 36, which were cleared under K070928 and Exactach® 12/14 Alumina Femoral Heads, which were cleared under K032964. #### Product Description: The MectaCer BIOLOX® forte Femoral Heads are ceramic ball heads intended for mechanical fixation to a mating hip stem and indicated for the treatment of patients who are candidates for total or partial hip arthroplasty to provide {1}------------------------------------------------ K073337 (pg 2 of 3) increased patient mobility and reduced pain by replacing the damaged hip joint, in primary or revision surgery. The MectaCer BIOLOX® forte Femoral Heads consist of High Purity Aluminium Oxyde Ceramic, Al2 O3 per standard ISO 6474:1994, Implants for surgery --Ceramics materials based on high purity alumina, Type A. The MectaCer BIOLOX® forte Femoral Heads are available in various sizes from 28, 32 and up to 36 mm diameters. ## Indications for Use: The MectaCer BIOLOX® forte Femoral Heads are intended for mechanical fixation to a mating hip stem and indicated for treatment of patients who are candidates for total or partial hip arthroplasty in primary or revision surgery. The patient should be skeletally mature. The patient's condition should be due to one or more of the following: - . Severely painful and/or disabled joint as a result of osteoarthritis, posttraumatic arthritis, rheumatoid arthritis, or psoriatic arthritis. - Congenital hip dysplasia . - Ankylosing spondylitis . - Avascular necrosis of the femoral head . - . Acute traumatic fracture of the femoral head or neck - Failure of previous hip surgery: joint reconstruction, internal fixation, . arthrodesis, hemiarthroplasty, surface replacement arthroplasty or total hip replacement where sufficient bone stock is present. ## Performance Testing No performance standards applicable to this device have been adopted under Section 514 of the Food, Drug and Cosmetic Act. Performance testing of the MectaCer BIOLOX® forte Femoral Heads was conducted in accordance with the following international standards and FDA quidance documents. - . ISO 6474:1994, Implants for surgery -- Ceramic materials based on high purity alumina - ISO 7206-10, 2003, Implants for surgery Partial and total hip-joint . prosthesis - Part 10: Determination of resistance to static load of modular femoral heads. - ASTM F-2009-00, Test Method for Determining the Axial Disassembly . Force of Taper Connections of Modular Prostheses - . AAMI/ANSI/ISO 11137 Sterilization of health care products – Radiation - FDA's "Guidance Documents for the Preparation of Premarket . Notifications for Ceramic Ball Hip Systems", January 10, 1995. ## Conclusion: The data and information provided in this submission support the conclusion that the MectaCer BIOLOX® forte Femoral Heads are substantially equivalent to its {2}------------------------------------------------ K073337 (pg 3 of 3) predicate devices, Plus Ceramic Ball Heads 28, 32 & 36, and Exactech® 12/14 Alumina Femoral Heads with respect to indications for use and technological characteristics. Actual device performance as tested conforms to applicable standards and FDA guidance. {3}------------------------------------------------ DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three stripes forming its body and wing. The eagle is facing right. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the eagle. FEB 13 2008 Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 MEDACTA International SA % Ms. Natalie J. Kennel NJK & Associates, Incorporated 13721 Via Tres Vista San Diego, California 92129 Re: K073337 Trade/Device Name: MectaCer BIOLOX® forte Femoral Heads Regulation Number: 21 CFR 888.3353 Regulation Name: Hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis. Regulatory Class: Class II Product Code: LZO Dated: November 27, 2007 Received: November 29, 2007 Dear Ms. Kennel: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 {4}------------------------------------------------ Page 2 - Ms. Natalie J. Kennel CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours, Mark N. Mulhausen Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {5}------------------------------------------------ # Indications for Use 510(k) Number (if known): K073337 Device Name: MectaCer BIOLOX® forte Femoral Heads Indications for Use: The MectaCer BIOLOX® forte Femoral Heads are intended for mechanical fixation to a mating hip stem and indicated for treatment of patients who are candidates for total or partial hip arthroplasty in primary or revision surgery. The patient should be skeletally mature. The patient's condition should be due to one or more of the following: - Severely painful and/or disabled joint as a result of osteoarthritis, post-. traumatic arthritis, rheumatoid arthritis, or psoriatic arthritis. - Congenital hip dysplasia . - . Ankylosing spondylitis - Avascular necrosis of the femoral head . - Acute traumatic fracture of the femoral head or neck . - Failure of previous hip surgery: joint reconstruction, internal fixation, . arthrodesis, hemiarthroplasty, surface replacement arthroplasty or total hip replacement where sufficient bone stock is present. Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Barbara Briems Division of Greeral, Restorative, Page _ of and Neurological Devices **510(k) Number** K073337
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%